What topics does this cannabis study cover?

This study covers research on: CBD, Inflammation, Neuroprotection.

Where was this research published?

Published in Inflammopharmacology on August 21, 2026.

CBDA may calm diet-linked brain inflammation in early research

Q: What did this research study find?

In high-fat-fed rats, *CBDA* was associated with **reduced arachidonic acid levels and inflammatory precursor proteins** in brain tissue.

The beneficial properties of CBDA in diet-induced neuroinflammation.

Inflammopharmacology • August 21, 2026 • Highly Relevant

🤖

AI Summary

This animal study examined whether cannabidiolic acid (CBDA) could reduce brain inflammation caused by a high-fat diet. Rats fed the high-fat diet and treated with CBDA showed lower levels of arachidonic acid and other proteins involved in inflammatory signaling, particularly in the posterior cortex. The treatment was also associated with improved insulin signaling in that brain region.

CBDA treatment coincided with the inactivation of glycogen synthase kinase 3 beta (GSK-3β) and changes in biomarkers linked to neurodegeneration in the cortex and cerebrospinal fluid. Metabolomic testing also found reduced levels of creatinine, phenylalanine, and sarcosine in treated high-fat-fed rats. The abstract reports no quantitative effect sizes or sample sizes, so these findings should be viewed as preliminary animal evidence—not proof that CBDA will prevent neuroinflammation or neurodegeneration in people. Human studies are needed before drawing practical conclusions for cannabis users.

💡 Key Findings

In high-fat-fed rats, CBDA was associated with reduced arachidonic acid levels and inflammatory precursor proteins in brain tissue.

Limited

35%

CBDA treatment was linked to improved insulin signaling, particularly in the posterior cortex, along with inactivation of GSK-3β.

Limited

35%

The treatment coincided with changes in neurodegenerative biomarkers in the cortex and cerebrospinal fluid, but the abstract does not establish that CBDA prevents neurodegeneration.

Limited

30%

Metabolomic analysis found lower creatinine, phenylalanine, and sarcosine levels in high-fat-fed rats given CBDA; the significance of these changes for human health remains uncertain.

Limited

30%

📄 Original Abstract

Cannabidiolic acid (CBDA) is a phytocannabinoid found in the Cannabis plant. Understanding the effects of CBDA is essential to uncover its full potential and possible health benefits. The study was conducted on rats receiving standard rat chow (control) and a high-fat diet (HFD). Half of the animals in each group were administered CBDA intragastrically. The total lipid fractions and arachidonic acid (AA) contents were measured in the frontal and posterior cortex, hippocampus, and subcortical nuclei using gas-liquid chromatography. The expression of proteins involved in neurodegenerative diseases and insulin signaling pathway proteins in the frontal and posterior cortex was measured using Immunoblotting. RT-PCR was used to assess the expression of pro-inflammatory pathway proteins in the same regions. Additionally, untargeted and targeted metabolomic analyses were performed on cerebrospinal fluid (CSF). The results showed that a decrease in arachidonic acid levels and pro-inflammatory precursor proteins after CBDA treatment in high-fat-fed rats was simultaneous with improved insulin signaling, particularly in the posterior cortex. Inactivation of glycogen synthase kinase 3 (GSK-3β) in this region was concomitant with changes in neurodegenerative biomarkers in the cortex and CSF. Metabolomic studies revealed a significant diminishment in creatinine, phenylalanine, and sarcosine levels in the HFD+CBDA group, suggesting it plays an important role in neurological disorders. The results suggest that CBDA has anti-inflammatory properties by reducing the synthesis of lipid inflammatory mediators, which are concomitant with improved insulin signaling and probably reduced neurodegeneration. Thus, CBDA could be considered as a part of future clinical treatment for many inflammatory conditions.

Paper Type

📄 Research

Publication

Journal: Inflammopharmacology
Published: August 21, 2026
PMID: 42627619
DOI: 10.1007/s10787-026-02358-4

Authors (8)

Karolina Konstantynowicz-Nowicka Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222, Bialystok, Poland. karolina.konstantynowicz-nowicka@umb.edu.pl.
Aleksandra Opęchowska Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222, Bialystok, Poland.
Maciej Domalewski Department of Physiology, Medical University of Bialystok, Mickiewicz Str. 2C, 15-222, Bialystok, Poland.
Magdalena Zabielska-Kaczorowska Department of Physiology, Medical University of Gdańsk, Dębinki Str. 1, 80-211, Gdańsk, Poland.
Aleksandra Bogucka Department of Physiology, Medical University of Gdańsk, Dębinki Str. 1, 80-211, Gdańsk, Poland.
+3 more authors